NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
LONDON & NEW YORK, July 29, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that…
Hashish Adventures in the Sixties
Review of Pipe Dreams and Smoke Screens (2025) by Richard Halford
Tuesday Brunch: Do underground guides know the legal risks?
Plus an update on the Amy Griffin law-suits, and why is Alfred North Whitehead so big in China?
FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.
For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found them...
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL…
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
CAMBRIDGE, Mass., July 28, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address…
Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics
This translational study integrated cell, blood and brain measures from people with treatment-resistant depression and healthy volunteers to examine shared biological changes linked to rapid antidepressant responses t...
Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study
This open-label pilot feasibility study (n=9) gave escalating oral doses of ibogaine, up to 400 mg, to adults with moderate to severe alcohol use disorder under continuous hospital monitoring. QTc changes occurred in ...
From “just say no” to just say nothing: 5 Questions for harm reduction educator Rhana Hashemi
Hashemi discusses her approach to drug education and what students want to know about psychedelics.
Does Music Matter More Than the Dose in Psychedelic Healing?
PLUS, best places to rave in the world, FIFA+psychedelics, and best shows to watch on psychedelics. [...] Read More... The post Does Music Matter More Than the Dose in Psychedelic Healing? appeared first on DoubleBlin...
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its board of directors has made a decision to target the agentic…
The Only Psychedelic Retreat That Earned an A
This Week's Sunday Insider: I reviewed over 100 psychedelic retreats, facilitators & clinics.
Dr Samuel Lee: the rise and possible fall of a psychedelic guru
The 'spiritual psychiatrist' faces manslaughter charges following a client's death
Why We Need Modern Rites of Passage
Welcome to The Psychedelic Blog.
The Psilomethoxin Saga Continues
A single lab claims to have found the compound that four others couldn't, and now the church is taking more people to court. [...] Read More... The post The Psilomethoxin Saga Continues appeared first on DoubleBlind Mag.